cbdMD (NYSEAMERICAN:YCBD) released its quarterly earnings results on Thursday. The company reported $0.45 EPS for the quarter, beating the consensus estimate of ($0.15) by $0.60, Fidelity Earnings reports. The business had revenue of $10.41 million during the quarter.
YCBD traded down $0.01 on Friday, reaching $1.14. 10,978 shares of the company traded hands, compared to its average volume of 1,265,310. cbdMD has a 52-week low of $0.99 and a 52-week high of $7.24.
A number of analysts recently commented on YCBD shares. Benchmark dropped their target price on shares of cbdMD from $9.00 to $7.00 and set a “speculative buy” rating on the stock in a report on Thursday, December 19th. Cantor Fitzgerald started coverage on shares of cbdMD in a report on Thursday, November 7th. They issued a “neutral” rating on the stock.
In related news, CEO Raymond Scott Coffman bought 125,000 shares of the business’s stock in a transaction that occurred on Tuesday, January 14th. The stock was purchased at an average cost of $1.09 per share, for a total transaction of $136,250.00. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. Insiders have purchased 150,000 shares of company stock worth $163,500 over the last ninety days.
cbdMD, Inc produces and distributes various cannibidiol (CBD) products in the United States. It operates through three segments: Products, Licensing, and Entertainment. The Products segment produces and markets CBD tinctures, capsules, gummies, bath bombs, vape oils, topical creams, and animal treats and oils under the cdbMD brand.
Further Reading: How is the LIBOR rate calculated?
Receive News & Ratings for cbdMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for cbdMD and related companies with MarketBeat.com's FREE daily email newsletter.